{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid+Leukemia&page=7", "query": { "condition": "Lymphoid Leukemia", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 2901, "total_pages": 291, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid+Leukemia&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid+Leukemia&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T23:58:37.377Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03678883", "title": "9-ING-41 in Patients With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Pancreatic Cancer", "Sarcoma", "Renal Cancer", "Refractory Cancer", "Refractory Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Pancreatic Adenocarcinoma", "Resistant Cancer", "Neoplasm Metastasis", "Neoplasm of Bone", "Neoplasm, Breast", "Neoplasm of Lung", "Neoplasms,Colorectal", "Neoplasms Pancreatic", "Malignant Glioma", "Malignancies", "Malignancies Multiple", "Bone Metastases", "Bone Neoplasm", "Bone Cancer", "Pancreas Cancer", "Pancreatic Neoplasms", "Breast Neoplasms", "Acute T Cell Leukemia Lymphoma" ], "interventions": [ { "name": "9-ING-41", "type": "DRUG" }, { "name": "Gemcitabine - 21 day cycle", "type": "DRUG" }, { "name": "Doxorubicin.", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Carboplatin.", "type": "DRUG" }, { "name": "Nab paclitaxel.", "type": "DRUG" }, { "name": "Paclitaxel.", "type": "DRUG" }, { "name": "Gemcitabine - 28 day cycle", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actuate Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2019-01-04", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-21T23:58:37.377Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03678883" }, { "nct_id": "NCT02477696", "title": "Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 533, "start_date": "2015-07-28", "completion_date": "2028-01-03", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-21T23:58:37.377Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Anaheim, California • Berkeley, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02477696" }, { "nct_id": "NCT01889186", "title": "A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "17p Deletion", "Cancer of the Blood and Bone Marrow" ], "interventions": [ { "name": "ABT-199 (Main Cohort)", "type": "DRUG" }, { "name": "ABT-199 (Safety Expansion Cohort)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 158, "start_date": "2013-06-27", "completion_date": "2020-12-15", "has_results": true, "last_update_posted_date": "2021-12-16", "last_synced_at": "2026-10-21T23:58:37.377Z", "location_count": 16, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01889186" }, { "nct_id": "NCT04506086", "title": "Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "B-precursor Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Current Wearable Heatlth Monitoring System (CWHMS)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 10, "start_date": "2021-08-26", "completion_date": "2024-09-16", "has_results": true, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-10-21T23:58:37.377Z", "location_count": 12, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04506086" }, { "nct_id": "NCT01400685", "title": "Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "B Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 34, "start_date": "2012-12", "completion_date": "2018-01", "has_results": false, "last_update_posted_date": "2018-01-25", "last_synced_at": "2026-10-21T23:58:37.377Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01400685" }, { "nct_id": "NCT03422393", "title": "Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Choi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-05-01", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2024-07-05", "last_synced_at": "2026-10-21T23:58:37.377Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03422393" }, { "nct_id": "NCT00003838", "title": "Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Acute Myelogenous Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "T-cell replete PBPC allograft", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "2 Years to 80 Years" }, "enrollment_count": 202, "start_date": "1999-04-15", "completion_date": "2020-06-18", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-21T23:58:37.377Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003838" }, { "nct_id": "NCT06561425", "title": "A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory B-cell Non-Hodgkin Lymphoma", "Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell" ], "interventions": [ { "name": "GLPG5101", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Lakefront Biotherapeutics NV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2022-03-09", "completion_date": "2026-05-27", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-21T23:58:37.377Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06561425" }, { "nct_id": "NCT06247540", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Transformed Chronic Lymphocytic Leukemia", "Richter Syndrome", "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma", "Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-03-29", "completion_date": "2031-12-29", "has_results": false, "last_update_posted_date": "2024-02-29", "last_synced_at": "2026-10-21T23:58:37.377Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06247540" }, { "nct_id": "NCT00900068", "title": "Blood Samples From Patients on a Clinical Trial to CINV During HSCT", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Nausea and Vomiting", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 9, "start_date": "2008-08", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-21T23:58:37.377Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900068" } ] }